7 completed, 1 terminated, 1 withdrawn. 8 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 7, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow CELLECTRA® 2000: new trials by email Literature Review of CELLECTRA® 2000 trials Research Report on CELLECTRA® 2000
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers INO-4800, INO-9112, CELLECTRA® 2000 - Coronavirus Infection | Phase 1 | Withdrawn | Inovio Pharmaceuticals | 2022-10-01 | 2022-11-17 | |
| Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure INO-4800, CELLECTRA® 2000, Placebo - Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Phase 2 / Phase 3 | Terminated | Inovio Pharmaceuticals | 1307 | 2020-11-30 | 2023-12-20 |
| INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) INO-3107, CELLECTRA® 2000 - Respiratory Papillomatosis | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 32 | 2020-10-07 | 2026-04-14 |
| Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 INO-4800, CELLECTRA® 2000, Saline-sodium citrate (SSC) buffer - Coronavirus Infection, SARS-CoV 2 | Phase 1 / Phase 2 | Completed | International Vaccine Institute | 79 | 2020-07-15 | 2022-07-18 |
| Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers INO-4800, CELLECTRA® 2000 - Coronavirus Infection | Phase 1 | Completed | Inovio Pharmaceuticals | 120 | 2020-04-03 | 2022-04-15 |
| Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers INO-4500, Placebo, CELLECTRA® 2000 - Lassa Fever | Phase 1 | Completed | Inovio Pharmaceuticals | 60 | 2019-05-09 | 2020-11-23 |
| A Study of INO-A002 in Healthy Dengue Virus-naive Adults INO-A002, CELLECTRA® 2000, Dengue Fever Antibodies (IgG) - Healthy Volunteers | Phase 1 | Completed | University of Pennsylvania | 30 | 2019-02-07 | 2023-12-14 |
| Therapeutic Vaccination in Treated HIV Disease PENNVAX-GP, INO-6145, INO-9012 - HIV-1-infection | Phase 1 / Phase 2 | Completed | Steven Deeks | 56 | 2018-08-01 | 2023-05-31 |
| INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma INO-5401, INO-9012, Atezolizumab - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 35 | 2018-07-24 | 2026-09-02 |
Coronavirus Infections (4) · COVID-19 (2) · Carcinoma, Transitional Cell (1) · Lassa Fever (1) · Recurrent respiratory papillomatosis (1)
Inovio Pharmaceuticals (6) · International Vaccine Institute (1) · Steven Deeks (1) · University of Pennsylvania (1)
United States (7) · Colombia (1) · Mexico (1) · South Korea (1)
Jeffrey Skolnik, MD (2) · Dr. Ning Jiang, MD PhD (1) · Eu Suk Kim, MD (1) · Jose Suaya (1) · Jose Suaya, MD (1) · Mammen Mammen, MD, FACP, FIDSA (1) · Myoung-don Oh, MD (1) · Pablo Tebas, MD (1) · Steven Deeks, MD (1)
PMID 33392485, PMID 35079784, PMID 37204106
U01AI131296 (1)